TY - JOUR
T1 - Risk of underdiagnosis of hypertension in schizophrenia patients
AU - Castillo-Sánchez, Miguel
AU - Fàbregas-Escurriola, Mireia
AU - Bergè-Baquero, Daniel
AU - Fernández-San Martín, MªIsabel
AU - Boreu, Quintí Foguet
AU - Goday-Arno, Albert
PY - 2018/2/17
Y1 - 2018/2/17
N2 - © 2017 Taylor & Francis. Aim: Arterial hypertension requires proper screening and management, and its underdiagnosis in patients with schizophrenia (SZ) and/or antipsychotic treatment has been postulated. The objective of the study is to assess whether there are differences in the proportion of screened patients with a blood pressure >140/90 mmHg that are undiagnosed or not confirmed later (risk of underdiagnosis). Methods: Cross-sectional study of clinical records from SIDIAPQ (Spain) during the 2006–2011 period. Three groups were studied: SZ, no SZ but under antipsychotic treatment, and control groups. Patients with established hypertension, cardiovascular disease, dementia, or diagnosis of SZ or starting with antipsychotic treatment during this period were excluded. Results: The SZ group had a lower risk of underdiagnosis than the control group (OR 0.91; 95% CI: 0.83–0.99; p < 0.05), at the expense of men (OR 0.8; 95% CI: 0.71–0.9; p < 0.001) and patients younger than 50 years of age (OR: 0.84; 95% CI: 0.74–0.93; p < 0.003). In the no SZ but under antipsychotic treatment group there were some differences, but not in the overall results. Conclusion: Preventive management of hypertension seemed to be sufficient for SZ and antipsychotic treatment patients. The lower prevalence of hypertension found in these groups may be due to other factors (blood pressure-lowering effect of psychoactive drugs or smoking) but these hypotheses must be evaluated with specific studies.
AB - © 2017 Taylor & Francis. Aim: Arterial hypertension requires proper screening and management, and its underdiagnosis in patients with schizophrenia (SZ) and/or antipsychotic treatment has been postulated. The objective of the study is to assess whether there are differences in the proportion of screened patients with a blood pressure >140/90 mmHg that are undiagnosed or not confirmed later (risk of underdiagnosis). Methods: Cross-sectional study of clinical records from SIDIAPQ (Spain) during the 2006–2011 period. Three groups were studied: SZ, no SZ but under antipsychotic treatment, and control groups. Patients with established hypertension, cardiovascular disease, dementia, or diagnosis of SZ or starting with antipsychotic treatment during this period were excluded. Results: The SZ group had a lower risk of underdiagnosis than the control group (OR 0.91; 95% CI: 0.83–0.99; p < 0.05), at the expense of men (OR 0.8; 95% CI: 0.71–0.9; p < 0.001) and patients younger than 50 years of age (OR: 0.84; 95% CI: 0.74–0.93; p < 0.003). In the no SZ but under antipsychotic treatment group there were some differences, but not in the overall results. Conclusion: Preventive management of hypertension seemed to be sufficient for SZ and antipsychotic treatment patients. The lower prevalence of hypertension found in these groups may be due to other factors (blood pressure-lowering effect of psychoactive drugs or smoking) but these hypotheses must be evaluated with specific studies.
KW - Antipsychotic agents
KW - cardiovascular diseases
KW - hypertension
KW - primary health care
KW - schizophrenia
U2 - 10.1080/10641963.2017.1346114
DO - 10.1080/10641963.2017.1346114
M3 - Article
VL - 40
SP - 167
EP - 174
JO - Clinical and Experimental Hypertension
JF - Clinical and Experimental Hypertension
SN - 1064-1963
IS - 2
ER -